Calliditas: The European CHMP opinion is a timely value trigger - Redeye

The positive CHMP opinion is both timely and expected. The next step is a Q3 European approval allowing Calliditas partner Stada to launch Kinpeygo in Europe. We can also look forward to the Part B readout in early 2023, which is likely to support both sales and the process of converting the conditional approval to unconditional approval.

Länk till analysen i sin helhet: https://www.redeye.se/research/842790/calliditas-the-european-chmp-opinion-is-a-timely-value-trigger?utm_source=finwire&utm_medium=RSS